- All
- November 19, 2026
- November 20, 2026
- November 21, 2026
- All
- 5th‑Floor Grand Ballroom
- S101
- S102
- S103
- S105
- S106
- S107
- S109
- S110
- S111
- S201
- S202
- S203
- S204
- S205
- S206
- S207
- V11
- V22
- V23
- V24
- V25
- InterContinental Ballroom 1
- All
- Plenary Session
- Oncology
- Minimally Invasive Surgery
- Stones
- Incontinence
- Robotic Surgery
- Clinical Research
- Basic and Translational Science
- Female Urology
- Andrology
- Nursing
- Infection
- Renal Transplantation
- Laser Surgery
- Community Urology
- Reconstructive Surgery
- Adrenals
- Pediatric Urology
- Smart Surgery
- Urological Engineering
- Special Session
- Prostate Cancer Pathfinders: Evidence into Action
- Prostate Neoplasms Session
- Benign Diseases Diagnosis & Treatment Session
- Urolithiasis Standardized Care Project
- Discovering Urological Frontiers
- Urology & Prostate
- Rising Leaders Urology
- Urologic Oncology Session
- Training Program for Urological Department
- Precision Care in Urologic Oncology
- Uro-Oncology Leadership & Innovation Forum
- Remote Session: Normalized Surgical Practice
- RCC Immunotherapy Session
- Intelligent Leadership in Prostate Care
- Bladder Cancer Session
- MP + SP in URO Seminar
- Benign Prostatic Hyperplasia Session
- Ingenuity Exploration
- Renal Cell Carcinoma Session
- Prostate Cancer Session
November 19, 2026
V24
| 1 | 12:00-12:10 |
Opening Remarks |
|
||||||||
| 1 | 12:10-12:30 |
Bone-Protective Therapy for Bone Metastases in Prostate Cancer: Initiating Early Intervention at the Asymptomatic Stage |
|
||||||||||||||
| 2 | 12:30-12:50 |
Discussion:1.What Are the Benefits of Early Initiation of Bone-Protective Therapy in Asymptomatic Patients with Prostate Cancer Bone Metastases? 2.What Insights Does the PEACE-3 Study Provide Regarding the Combination of Bone-Targeted Agents (BTAs) with Radionuclide and Endocrine Therapies? |
|
||||||||||||||
| 1 | 12:50-13:00 |
Summary |
|
||||||||
| 1 | 16:00-16:05 |
Opening Remarks |
|
||||||||
| 1 | 16:05-16:20 |
Spotlight on the Cutting Edge: Recent Advances in the Diagnosis and Treatment of BPH/LUTS |
|
|||||||||||||||||
| 2 | 16:20-16:35 |
Interpretation of the 2026 CUA Guidelines on Benign Prostatic Hyperplasia |
|
|||||||||||||||||
| 3 | 16:35-16:45 |
Background and Significance of the Development of the Chinese Expert Consensus on the Diagnosis and Treatment of Underactive bladder |
|
|||||||||||||||||
| 4 | 16:45-16:55 |
Interpretation of the Chinese Expert Consensus on the Diagnosis and Treatment of Bladder Hypofunction |
|
|||||||||||||||||
| 5 | 16:55-17:05 |
Discussion |
|
|||||||||||||||||
| 1 | 17:05-17:20 |
Development and Application of Noninvasive Precision Subtyping Technology for Primary Aldosteronism |
|
||||||||||||||
| 2 | 17:20-17:35 |
Surgical Considerations of Retroperitoneal Approach for Right Renal Carcinoma in Situs Inversus Totalis |
|
||||||||||||||
| 3 | 17:35-17:50 |
The Drum Tower’s Experience with Thousand Cases of Rezūm Therapy |
|
||||||||||||||
| 4 | 17:50-18:00 |
Discussion |
|
||||||||||||||
| 5 | 18:00-18:05 |
Summary |
|
||||||||||||||